Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology 2026-06-22
  2. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study 2024-04-06

Studies

2 studies carry this tag.

Date range

2024 to 2026

Top journals

  • Clinica chimica acta; international journal of clinical chemistry 1
  • Frontiers in psychiatry 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Frontiers in psychiatry 2026-06-22 Treatments

    This study provides real-world evidence on the risk profile of lecanemab, highlighting the importance of continued safety monitoring.

  2. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Clinica chimica acta; international journal of clinical chemistry 2024-04-06 Biomarkers

    Our results confirmed the diagnostic performance of individual plasma biomarkers Aβ42/Aβ40, p-tau181, NfL, and GFAP in Chinese dementia patients and noted that a combination of these biomarkers may be more accurate in identifying FTD/PSP patients and distinguishing AD from non-AD dementia.

All topic tags with their study counts